Clinical Trials Logo

Filter by:
NCT ID: NCT00352183 Completed - Clinical trials for Cardiovascular Diseases

Comparison of the Combination of Fenofibrate and 40 mg Simvastatin Versus 40 mg Simvastatin Monotherapy

Start date: January 2006
Phase: Phase 3
Study type: Interventional

Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia. The overall objective of the study is to evaluate the efficacy and safety of combining fenofibrate and simvastatin in patients with mixed hyperlipidemia at risk of cardiovascular diseases.

NCT ID: NCT00350415 Completed - Ulcerative Colitis Clinical Trials

A Double Blind Study for the Treatment of Acute Ulcerative Colitis

Start date: June 2006
Phase: Phase 3
Study type: Interventional

A Double-blind, Randomized, 6-week, Parallel-group Design Clinical trial to assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg mesalamine tablet) for the Treatment of Moderately Active Ulcerative Colitis (ASCEND III).

NCT ID: NCT00348192 Completed - Alzheimer's Disease Clinical Trials

SB-742457 And Donepezil In Alzheimer's Disease

Start date: May 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's Disease. SB-742457 is a new treatment which is thought to increase the levels of certain chemicals in the brain that are often decreased in patients with Alzheimer's Disease.

NCT ID: NCT00347425 Completed - Clinical trials for Schizophrenia and Schizoaffective Disorder

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

Start date: December 2006
Phase: Phase 3
Study type: Interventional

The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.

NCT ID: NCT00345618 Completed - Thrombosis Clinical Trials

Clinical Study Assessing SSR126517E Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

CASSIOPEA
Start date: June 2006
Phase: Phase 3
Study type: Interventional

Objectives are to evaluate whether idrabiotaparinux (SSR126517E) is as least as effective as a standard warfarin treatment to prevent recurrence of venous thromboembolic events (VTE) in patients with symptomatic pulmonary embolism (PE) with or without symptomatic deep venous thrombosis (DVT) and to assess its safety (bleedings) versus warfarin.

NCT ID: NCT00342316 Completed - Clinical trials for Acute Myeloid Leukemia

Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia

Start date: December 18, 2003
Phase: N/A
Study type: Interventional

This study compares overall survival between patients with acute myeloid leukemia, who are in complete remission following initial treatment with chemotherapy and whose remission is maintained either with a transplantation of stem cells obtained from a sibling or unrelated donor or with standard treatment, which is additional chemotherapy. The study hypothesis is that the group transplanted with stem cells from a donor will have a superior survival compared with patients treated with standard of care.

NCT ID: NCT00337818 Completed - Clinical trials for Cervical Intraepithelial Neoplasia

Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women

Start date: June 2006
Phase: Phase 3
Study type: Interventional

The study will be extended for subjects who received all three doses of vaccine in Finland, Denmark and Estonia to determine long-term safety and immunogenicity of the HPV-16/18 vaccine. Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection often goes away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. If a woman is not infected by HPV, it is very unlikely that she will get cervical cancer. This study will evaluate the consistency of consecutive vaccine lots and the non-inferiority of modified manufacturing processes of GlaxoSmithKline Biologicals HPV-16/18 vaccine and the vaccine safety, over 12 months, in young adolescents and women of 10-25 years of age at study start.

NCT ID: NCT00335452 Completed - Angina Unstable Clinical Trials

Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS

CURRENT/OASIS7
Start date: June 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).

NCT ID: NCT00335374 Completed - Clinical trials for Early Stage Parkinson's Disease

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Start date: August 2007
Phase: Phase 3
Study type: Interventional

This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial

NCT ID: NCT00335166 Completed - Clinical trials for Early Stage Parkinson Disease

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

Start date: November 2006
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.